These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 31810731

  • 1. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T, Tran A, Webster AC, Klarenbach SW, Gill J, Chadban S, Morton R.
    Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
    [Abstract] [Full Text] [Related]

  • 2. Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study.
    Ying T, Gill J, Webster A, Kim SJ, Morton R, Klarenbach SW, Kelly P, Ramsay T, Knoll GA, Pilmore H, Hughes G, Herzog CA, Chadban S, Gill JS.
    Am Heart J; 2019 Aug; 214():175-183. PubMed ID: 31228771
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of ankle-brachial index screening in patients with coronary artery disease to optimize medical management.
    Minami HR, Itoga NK, George EL, Garcia-Toca M.
    J Vasc Surg; 2021 Dec; 74(6):2030-2039.e2. PubMed ID: 34175383
    [Abstract] [Full Text] [Related]

  • 4. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
    Puttarajappa CM, Hariharan S, Smith KJ.
    Clin J Am Soc Nephrol; 2018 Feb 07; 13(2):290-298. PubMed ID: 29025787
    [Abstract] [Full Text] [Related]

  • 5. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW, Tangri N, Tan Z, James MT, Lavallee BDA, Chartrand CD, McLeod LL, Dart AB, Rigatto C, Komenda PVJ.
    Kidney Int; 2017 Jul 07; 92(1):192-200. PubMed ID: 28433383
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men.
    Nolte JE, Neumann T, Manne JM, Lo J, Neumann A, Mostardt S, Abbara S, Hoffmann U, Brady TJ, Wasem J, Grinspoon SK, Gazelle GS, Goehler A.
    Eur J Prev Cardiol; 2014 Aug 07; 21(8):972-9. PubMed ID: 23539717
    [Abstract] [Full Text] [Related]

  • 7. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E, Virtanen O, Väätäinen S, Briere JB, Bowrin K, Millier A.
    Adv Ther; 2020 Jul 07; 37(7):3348-3369. PubMed ID: 32519113
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An economic evaluation of an abdominal aortic aneurysm screening program in Italy.
    Giardina S, Pane B, Spinella G, Cafueri G, Corbo M, Brasseur P, Orengo G, Palombo D.
    J Vasc Surg; 2011 Oct 07; 54(4):938-46. PubMed ID: 21820837
    [Abstract] [Full Text] [Related]

  • 12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 07; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.
    Clin Ther; 2012 Jul 07; 34(7):1531-43. PubMed ID: 22742885
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL, Magnuson EA, Serruys PW, Campos CM, Wang K, van Klaveren D, Farooq V, Abdallah MS, Li H, Vilain KA, Steyerberg EW, Morice MC, Dawkins KD, Mohr FW, Kappetein AP, Cohen DJ, SYNTAX trial investigators.
    Heart; 2015 Dec 07; 101(24):1980-8. PubMed ID: 26552756
    [Abstract] [Full Text] [Related]

  • 15. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P, Cristeau O, Bowrin K, Briere JB.
    Cardiovasc Res; 2020 Sep 01; 116(11):1918-1924. PubMed ID: 31807773
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F, Lau T, Luo N.
    Nephrology (Carlton); 2016 Aug 01; 21(8):669-77. PubMed ID: 26566750
    [Abstract] [Full Text] [Related]

  • 17. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
    Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, D'Souza R, Welch K, Stein K.
    Health Technol Assess; 2007 May 01; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
    [Abstract] [Full Text] [Related]

  • 18. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.
    Nephrol Dial Transplant; 2007 Oct 01; 22(10):2867-78. PubMed ID: 17595182
    [Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals.
    van Kempen BJ, Spronk S, Koller MT, Elias-Smale SE, Fleischmann KE, Ikram MA, Krestin GP, Hofman A, Witteman JC, Hunink MG.
    J Am Coll Cardiol; 2011 Oct 11; 58(16):1690-701. PubMed ID: 21982314
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.